Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

434 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
C-Aryl 5a-carba-β-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
Ohtake Y, Sato T, Matsuoka H, Kobayashi T, Nishimoto M, Taka N, Takano K, Yamamoto K, Ohmori M, Higuchi T, Murakata M, Morikawa K, Shimma N, Suzuki M, Hagita H, Ozawa K, Yamaguchi K, Kato M, Ikeda S. Ohtake Y, et al. Among authors: ohmori m. Bioorg Med Chem. 2012 Jul 1;20(13):4117-27. doi: 10.1016/j.bmc.2012.04.053. Epub 2012 May 4. Bioorg Med Chem. 2012. PMID: 22652255
5a-Carba-β-D-glucopyranose derivatives as novel sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
Ohtake Y, Sato T, Matsuoka H, Nishimoto M, Taka N, Takano K, Yamamoto K, Ohmori M, Higuchi T, Murakata M, Kobayashi T, Morikawa K, Shimma N, Suzuki M, Hagita H, Ozawa K, Yamaguchi K, Kato M, Ikeda S. Ohtake Y, et al. Among authors: ohmori m. Bioorg Med Chem. 2011 Sep 15;19(18):5334-41. doi: 10.1016/j.bmc.2011.08.005. Epub 2011 Aug 8. Bioorg Med Chem. 2011. PMID: 21873071
Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
Ohtake Y, Sato T, Kobayashi T, Nishimoto M, Taka N, Takano K, Yamamoto K, Ohmori M, Yamaguchi M, Takami K, Yeu SY, Ahn KH, Matsuoka H, Morikawa K, Suzuki M, Hagita H, Ozawa K, Yamaguchi K, Kato M, Ikeda S. Ohtake Y, et al. Among authors: ohmori m. J Med Chem. 2012 Sep 13;55(17):7828-40. doi: 10.1021/jm300884k. Epub 2012 Aug 28. J Med Chem. 2012. PMID: 22889351
Design and evaluation of new antipsoriatic antedrug candidates having 16-en-22-oxa-vitamin D3 structures.
Shimizu K, Kawase A, Haneishi T, Kato Y, Kinoshita K, Ohmori M, Furuta Y, Emura T, Kato N, Mitsui T, Yamaguchi K, Morita K, Sekiguchi N, Yamamoto T, Matsushita T, Shimaoka S, Sugita A, Morikawa K. Shimizu K, et al. Among authors: ohmori m. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3323-9. doi: 10.1016/j.bmcl.2006.03.014. Epub 2006 Apr 21. Bioorg Med Chem Lett. 2006. PMID: 16630723
Discovery of [5-Amino-1-(2-methyl-3H-benzimidazol-5-yl)pyrazol-4-yl]-(1H-indol-2-yl)methanone (CH5183284/Debio 1347), An Orally Available and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor.
Ebiike H, Taka N, Matsushita M, Ohmori M, Takami K, Hyohdoh I, Kohchi M, Hayase T, Nishii H, Morikami K, Nakanishi Y, Akiyama N, Shindoh H, Ishii N, Isobe T, Matsuoka H. Ebiike H, et al. Among authors: ohmori m. J Med Chem. 2016 Dec 8;59(23):10586-10600. doi: 10.1021/acs.jmedchem.6b01156. Epub 2016 Nov 29. J Med Chem. 2016. PMID: 27933954
Biological activity of 24,24-difluoro-1 alpha, 25-dihydroxyvitamin D3 and 1 alpha, 25-dihydroxyvitamin D3-26,23-lactone in inducing differentiation of human myeloid leukemia cells.
Shiina Y, Abe E, Miyaura C, Tanaka H, Yamada S, Ohmori M, Nakayama K, Takayama H, Matsunaga I, Nishii Y, DeLuca HF, Suda T. Shiina Y, et al. Among authors: ohmori m. Arch Biochem Biophys. 1983 Jan;220(1):90-4. doi: 10.1016/0003-9861(83)90390-9. Arch Biochem Biophys. 1983. PMID: 6572492
434 results